CUV.AU Clinuvel Pharmaceuticals Ltd

Healthcare Biotechnology Australian Securities Exchange
7.22 AUD
Close of Nov 1, 2026
6.62 13.40
Market cap
AUD 365M
P/E
10.8x
P/B
1.34x
ROE
12.4%
Dividend yield
0.69%
Fundamental score
3.8/5

Ratios use the latest price and the fiscal year ending Jun 2026.

Is CUV.AU undervalued?

Graham number
Price7.22
Graham value9.03
Discount20.0%

CUV.AU trades 20.0% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Clinuvel Pharmaceuticals Ltd fundamental analysis

18 of 22 checks passed

ROE 1/2

Moderate return on equity (12.4%), between 10% and 20%.

ROA 1/1

Return on assets (11.5%) is above the industry median (-51.4%).

Profit Consistency 2/2

Profitable for 10 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Last year's EPS growth (-5.3%) is not above the 5-year average (7.1% a year).

Earnings Growth vs Industry 0/1

Last year's EPS growth (-5.3%) is below the industry median (-5.3%).

Revenue Growth 1/2

Revenue grew 6.3% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (0.7%), 40% or less.

Debt Trend 1/1

Debt to equity has not risen over the past 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 1/1

EBIT is 498.7x against interest expense, well covered.

PE vs Market 1/1

PE (10.8x) is below the market median (15.0x).

PE vs Industry 1/1

PE (10.8x) is below the industry median (16.3x).

PBV 1/1

Price to book (1.3x) is below the industry median (4.4x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 14.4, limit 22.5).

PEG 0/1

PEG on 5-year earnings growth is 1.53, above 1.

Dividend Yield 0/2

Dividend yield (0.7%) is in the bottom 25% of dividend payers in the market.

Dividend Stability 2/2

Dividends paid without a cut of more than 10% for 10 years.

Dividend Growth 1/1

Dividends paid grew over the past 5 years.

Payout Ratio 1/1

Payout ratio is 7.4%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Clinuvel Pharmaceuticals Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Clinuvel Pharmaceuticals Ltd

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimu…

Full company profile